Michael Studnicka

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study

Erik Folch, Michael A. Pritchett, Michael Nead et al. · Journal of Thoracic Oncology · 2018 · 407 citations · Full text

Medicine, Clinical Sciences, Radiology +13

Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit

Sylvia Hartl, José Luís López-Campos, Francisco Pozo-Rodrı́guez et al. · European Respiratory Journal · 2015 · 240 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Ultrastructural characterization of cystic fibrosis sputum using atomic force and scanning electron microscopy

Reinhard Manzenreiter, Ferry Kienberger, Verónica Marcos et al. · Journal of Cystic Fibrosis · 2011 · 199 citations

Medicine, Biophysics, Cell Biology +17